Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeri Kim

Showing results (71-80 of 103) with videos related to

Pageof 11
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancerChristos N Papandreou, Danai D Daliani, Darrell Nix, et al.
International Journal of Radiation Oncology, Biology, Physics|December 13, 2017
Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life OutcomesSteven J Frank, Thomas J Pugh, Pierre Blanchard, et al.
Oncotarget|June 23, 2016
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancerTheodoros Karantanos, Styliani Karanika, Jianxiang Wang, et al.
European Urology Oncology|April 6, 2024
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel TrialFred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2013
Platinum-based chemotherapy for variant castrate-resistant prostate cancerAna M Aparicio, Andrea L Harzstark, Paul G Corn, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancerMyrto Boukovala, Nicholas Spetsieris, Justin A Weldon, et al.
Journal of the National Cancer Institute|February 27, 2009
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancerDimitra Tsavachidou, Timothy J McDonnell, Sijin Wen, et al.
Nature Communications|August 29, 2020
Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancerJody Vykoukal, Johannes F Fahrmann, Justin R Gregg, et al.
Clinical Genitourinary Cancer|July 18, 2020
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate CancerNicholas Spetsieris, Myrto Boukovala, Justin A Weldon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2017
Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate CancerWei Zhang, Bo Liu, Wenhui Wu, et al.
Pageof 11

Showing results (71-80 of 103) with videos related to

Sort By:
Pageof 11
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 1, 2004
Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancerChristos N Papandreou, Danai D Daliani, Darrell Nix, et al.
International Journal of Radiation Oncology, Biology, Physics|December 13, 2017
Prospective Phase 2 Trial of Permanent Seed Implantation Prostate Brachytherapy for Intermediate-Risk Localized Prostate Cancer: Efficacy, Toxicity, and Quality of Life OutcomesSteven J Frank, Thomas J Pugh, Pierre Blanchard, et al.
Oncotarget|June 23, 2016
Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancerTheodoros Karantanos, Styliani Karanika, Jianxiang Wang, et al.
European Urology Oncology|April 6, 2024
Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel TrialFred Saad, Andrew J Armstrong, Mototsugu Oya, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 8, 2013
Platinum-based chemotherapy for variant castrate-resistant prostate cancerAna M Aparicio, Andrea L Harzstark, Paul G Corn, et al.
European Journal of Cancer (Oxford, England : 1990)|January 28, 2020
A candidate androgen signalling signature predictive of response to abiraterone acetate in men with metastatic castration-resistant prostate cancerMyrto Boukovala, Nicholas Spetsieris, Justin A Weldon, et al.
Journal of the National Cancer Institute|February 27, 2009
Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancerDimitra Tsavachidou, Timothy J McDonnell, Sijin Wen, et al.
Nature Communications|August 29, 2020
Caveolin-1-mediated sphingolipid oncometabolism underlies a metabolic vulnerability of prostate cancerJody Vykoukal, Johannes F Fahrmann, Justin R Gregg, et al.
Clinical Genitourinary Cancer|July 18, 2020
A Phase 2 Trial of Abiraterone Followed by Randomization to Addition of Dasatinib or Sunitinib in Men With Metastatic Castration-Resistant Prostate CancerNicholas Spetsieris, Myrto Boukovala, Justin A Weldon, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 16, 2017
Targeting the MYCN-PARP-DNA Damage Response Pathway in Neuroendocrine Prostate CancerWei Zhang, Bo Liu, Wenhui Wu, et al.
Pageof 11